Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-06-23
Target enrollment:
Participant gender:
Summary
To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in
patients with recurrent/metastatic esophageal squamous cell carcinoma.